Catalyst Pharmaceutical CPRX Amortization Expenses Of Intangible Asset
Amortization Expenses Of Intangible Asset at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept cprx:AmortizationExpensesOfIntangibleAsset.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's amortization expenses of intangible asset.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's amortization expenses of intangible asset?
- Catalyst Pharmaceutical (CPRX) reported amortization expenses of intangible asset of $9.7M in Q1 2026.
- How has Catalyst Pharmaceutical's amortization expenses of intangible asset changed year-over-year?
- Catalyst Pharmaceutical's amortization expenses of intangible asset increased by 3.8% year-over-year, from $9.35M to $9.7M.
- What does amortization expenses of intangible asset mean?
- This represents the periodic allocation of the cost of intangible assets, such as patents, licenses, or acquired intellectual property, over their estimated useful lives. For a biopharmaceutical company, this reflects the non-cash expense associated with the gradual consumption of the value of acquired drug rights or regulatory approvals. Monitoring this helps investors understand the impact of past acquisitions on current profitability without the influence of cash-based operating costs.